NCT02556593

IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases

IMRT Combined With Erlotinib Compared With Whole-brain Radiotherapy for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is to assess the efficacy of IMRT combined with erlotinib compared with whole-brain radiotherapy for EGFR wild type non-small cell lung cancer with 4-10 brain metastases.

Detailed description

This study is to assess the efficacy of IMRT combined with erlotinib compared with whole-brain radiotherapy for EGFR wild type non-small cell lung cancer with 4-10 brain metastases. All patients recruited will be randomly assigned into two groups. Patients in experimental group will receive daily IMRT at 45 Gy in 15 fractions to brain metastases, combined with daily erlotinib of 150mg for three weeks. Patients in control group will receive daily whole-brain radiotherapy at 30 Gy in 10 fractions.

Conditions

• Non-Small Cell Lung Carcinoma

Interventions

Type	Name	Description
RADIATION	IMRT	Daily IMRT at 45 Gy in 15 fractions to brain metastases
RADIATION	WBRT	3DCRT at 30 Gy in 10 fractions to whole brain
DRUG	erlotinib	erlotinib 150mg daily

Timeline

• Start date: 2015-09-01
• Primary completion: 2019-04-01
• Completion: 2019-04-01
• First posted: 2015-09-22
• Last updated: 2019-04-12

Locations

1 site across 1 country: China